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Binding of neomycin-class aminoglycoside antibiotics to mutant
ribosomes with alterations in the A site of 16S rRNA
Abstract
Aminoglycoside antibiotics that bind to the aminoacyl-tRNA site (A site) of the ribosome are composed
of a common neamine core in which a glycopyranosyl ring is attached to position 4 of a
2-deoxystreptamine moiety. The core is further substituted by one (ribostamycin), two (neomycin and
paromomycin), or three (lividomycin A) additional sugars attached to position 5 of the
2-deoxystreptamine. To study the role of rings III, IV, and V in aminoglycoside binding, we used
isogenic Mycobacterium smegmatis DeltarrnB mutants carrying homogeneous populations of mutant
ribosomes with alterations in the 16S rRNA A site. MICs were determined to investigate drug-ribosome
interactions, and the results were compared with that of the previously published crystal structure of
paromomycin bound to the ribosomal A site. Our analysis demonstrates that the stacking interaction
between ring I and G1491 is largely sequence independent, that rings III and IV each increase the
strength of drug binding to the ribosome, that ring IV of the 6'-NH3+ aminoglycosides compensates for
loss of interactions between ring II and U1495 and between ring III and G1491, that the
aminoglycosides rely on pseudo-base pairing between ring I and A1408 for binding independently of the
number of sugar rings attached to the neamine core, that addition of ring V to the 6'-OH
4,5-aminoglycoside paromomycin does not alter the mode of binding, and that alteration of the
U1406.U1495 wobble base pair to the Watson-Crick interaction pair 1406C-1495G yields ribosomal
drug susceptibilities to 4,5-aminoglycosides comparable to those seen with the wild-type A site.
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Aminoglycoside antibiotics that bind to the aminoacyl-tRNA site (A site) of the ribosome are composed of
a common neamine core in which a glycopyranosyl ring is attached to position 4 of a 2-deoxystreptamine
moiety. The core is further substituted by one (ribostamycin), two (neomycin and paromomycin), or three
(lividomycin A) additional sugars attached to position 5 of the 2-deoxystreptamine. To study the role of rings
III, IV, and V in aminoglycoside binding, we used isogenic Mycobacterium smegmatis rrnB mutants carrying
homogeneous populations of mutant ribosomes with alterations in the 16S rRNA A site. MICs were determined
to investigate drug-ribosome interactions, and the results were compared with that of the previously published
crystal structure of paromomycin bound to the ribosomal A site. Our analysis demonstrates that the stacking
interaction between ring I and G1491 is largely sequence independent, that rings III and IV each increase the
strength of drug binding to the ribosome, that ring IV of the 6-NH3
 aminoglycosides compensates for loss of
interactions between ring II and U1495 and between ring III and G1491, that the aminoglycosides rely on
pseudo-base pairing between ring I and A1408 for binding independently of the number of sugar rings attached
to the neamine core, that addition of ring V to the 6-OH 4,5-aminoglycoside paromomycin does not alter the
mode of binding, and that alteration of the U1406 · U1495 wobble base pair to the Watson-Crick interaction
pair 1406C-1495G yields ribosomal drug susceptibilities to 4,5-aminoglycosides comparable to those seen with
the wild-type A site.
Aminoglycosides form a large family of water-soluble, polycationic
amino sugars which are used as broad-spectrum antibacterial agents
(14, 15). Common to all aminoglycosides is the neamine core. The
neamine core is composed of a six-membered cyclitol (2-deoxy-
streptamine; ring II) glycosidically linked to a glucopyranosyl (ring I).
Aminoglycosides target the ribosome by direct interaction with
rRNA and they affect protein synthesis by inducing codon misread-
ing and by inhibiting translocation of the tRNA-mRNA complex
from the A to the P site (4, 15, 18, 28).
Helix 44 is located in the 1400 to 1500 region of 16S rRNA
(Escherichia coli numbering is used throughout this article) and
has been identified as the site of codon-anticodon interaction (A
site) by a number of studies (3, 17, 19, 32). Although A-site-bound
tRNA and aminoglycosides protect the same nucleotides in the
decodingregion,namelyA1408,A1492,A1493,andG1494,amino-
glycosides do not act by sterically hindering the binding of the
tRNA to the ribosome. Instead, they interfere with the decoding
process by inducing conformational alterations of the ribosomal
A site (2, 19). Upon drug binding, nucleotides A1492 and A1493
flip out from helix 44; this change in conformation is normally
only observed after the formation of a cognate tRNA-mRNA
complex (2, 19, 20). Bulging out of A1492 and A1493 is most
likely an essential step in aminoglycoside action, as it explains the
miscoding properties of these drugs (4).
The neamine core of the aminoglycosides is essential for
drug activity (4, 6). Nuclear magnetic resonance studies have
revealed that rings I and II of the 4,5-aminoglycosides are
sufficient to confer specific binding to a model A site RNA (6).
A1408 and base pairs C1409-G1491 and U1406 · U1495 rep-
resent important elements of the drug binding pocket (Fig. 1).
Ring I forms two direct hydrogen bonds to the Watson-Crick
side of A1408 and is involved in a stacking interaction with
G1491. Ring II participates in a network of hydrogen bond
contacts of which the interactions between the 1-amino group
and O-4 of U1495 and between the 3-amino group and N-7 of
G1494 are sequence specific.
The neamine core makes additional direct or water-bridged
hydrogen bond contacts to the phosphate backbone of A1492 and
A1493 (2, 29, 30). Additional sugars (rings III, IV, and V) are
attached to position 5 of the 2-deoxystreptamine moiety. The
contacts of ring III are characterized by two direct hydrogen
bonds, with N-7 of G1491 and with N-4 of C1407, linking the two
RNA strands of helix 44 together. Ring IV is mainly involved in
non-sequence-specific electrostatic interactions with the phos-
phate backbone, but the exact positioning of this ring remains to
be established (2, 27). Recently, the structures of complexes be-
tween oligonucleotides containing the A site and neamine, neo-
mycin, and lividomycin A (8) have been solved (Fig. 1).
RNA sequence determinants for aminoglycoside binding to
the ribosomal A site have mostly been defined using model
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RNA oligonucleotides (6, 7, 9, 13, 16, 26). Data on in vivo
mutagenesis of the ribosomal A site are scarce and compro-
mised by limitations in Escherichia coli, which is frequently
used as the model in ribosomal genetics. In particular, several
rRNA nucleotides involved in forming the drug binding site
could not be subjected to in vivo mutagenesis due to nonvi-
ability of the mutations in E. coli, e.g., U1495A, U1495C,
G1491A, and C1409G (5, 25). These limitations were over-
come with the development of the Mycobacterium smegmatis
rrnB system (21–24, 27). To analyze the contributions of rings
III, IV, and V to the binding of 4,5-aminoglycosides, we ex-
tended our experiments using M. smegmatis rrnB strains car-
rying a large set of mutations within the decoding site.
MATERIALS AND METHODS
Bacterial strains and DNA techniques. The conditions for selective plating
and RecA-mediated homologous recombination to obtain mutant strains of M.
smegmatis rrnB (for a list of mutants, see Table 1 and Fig. 2) were described
previously (23). After mutant selection the strains were cultured on LB agar
plates. Nucleic acid sequencing was used to verify that the point mutations had
been introduced into the single functional rRNA operon of M. smegmatis rrnB.
Taq cycle sequencing was done with fluorescently labeled nucleotides according
to the manufacturer’s instructions (Applied Biosystems).
Determination of the MICs. Strains of M. smegmatis rrnB were cultured on
LB agar plates. Single-colony cultures, grown in LB medium supplemented with
0.05% Tween 80, were used for MIC tests in a microtiter plate format; at least
three independent clones were analyzed per mutation. To 200 l of starting
cultures with an optical density at 600 nm of 0.025, the antibiotics to be tested
were added in twofold series of dilutions ranging from 0.25 to 1,024 g/ml.
Paromomycin (P-9297), lividomycin (L-4518), neomycin (N-6386), and ribostamy-
cin (R-2255) were obtained from Sigma; neamine (158966) was from ICN
Biomedicals. The MIC is defined as the drug concentration at which the growth
of the cultures is completely inhibited after incubation at 37°C. Cells were
incubated for a period corresponding to 24 generations; the wild type has a
generation time of 3 h, and the generation time of the mutants investigated was
in the range of 3 to 6 h (U1495A, 8 h).
RESULTS
Experimental system. The 4,5-disubstituted 2-deoxystreptamines
investigated share close structural similarities. The common core
of the 4,5-aminoglycosides is composed of a 2-deoxystreptamine
and a glycopyranosyl ring. The chemical group linked to the 6
position of ring I separates the 4,5-aminoglycosides into two sub-
classes: the 6-amino subclass (neamine, ribostamycin, and neo-
mycin) and the 6-hydroxy subclass (paromomycin and lividomy-
cin). The diversity within these two subclasses is based on the
number of sugar moieties attached to position 5 of ring II: ribosta-
mycin consists of neamine with one additional sugar attached to
ring II; addition of a fourth ring to ring III of ribostamycin gives
FIG. 1. A: Superposition of neamine (gray ball and sticks) and
ribostamycin (orange) molecules docked in the minimal A site of the
ribostamycin crystal structure (orange). B: Superposition of the livido-
mycin A (magenta ball and sticks) and paromomycin (cyan ball and
sticks) molecules docked in the minimal A site of the paromomycin
crystal structure (cyan). C: Superposition of the neomycin (yellow ball
and sticks) and paromomycin (cyan ball and sticks) molecules docked
in the minimal A site of the paromomycin crystal structure (cyan).
Data on crystal structures are from references 8 and 29.
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rise to neomycin. Except for the 6 position, paromomycin is
identical to neomycin; an additional fifth ring attached to paromo-
mycin gives rise to lividomycin (for a list of drug structures, see
Fig. 3 and 4). The number of charges and the nature of the
substituent at position 6 are identical for neamine and ribostamy-
cin and for paromomycin and lividomycin; in both cases, however,
the number of rings varies.
Mutagenesis in M. smegmatis rrnB results in isogenic strains car-
rying homogeneous populations of mutant ribosomes (for a list of
mutant strains, see Table 1 and Fig. 2). MICs were determined to
investigate ribosomal drug susceptibility. Data interpretation for
neamine, ribostamycin, neomycin, paromomycin, and lividomycin
was based on available X-ray structural information (2, 8, 29).
The drug susceptibility measurements given in Table 2 (see
also comparison graphs in Fig. 3 and 4) reveal that in wild-type
M. smegmatis rrnB the activity of the 4,5-aminoglycosides
correlates with the number of sugar rings attached to the
neamine core. Addition of a third or fourth ring increases the
activity of the drug by approximately eightfold each. However,
the presence of an additional fifth ring, as in lividomycin, does
not markedly increase drug activity.
The pseudo-base pair between ring I and A1408 was recently
defined as a critical interaction for aminoglycoside binding
(22, 29, 31). Independent of the number of rings attached to
the neamine core, disruption of the pseudo-base pair by the
A1408G alteration prevents the binding of all 4,5-aminogly-
cosides with a 6-NH3
 group (see Table 2). In contrast, for
the 6-OH aminoglycosides (paromomycin and lividomycin)
the hydroxyl group at position 6 of ring I is likely to become
an H-bond acceptor for N-1 or N-2 of A1408G, as discussed
previously (22, 29, 31). Thus, these drugs can bind to the
target site in presence of A1408G (see Table 2).
Interactions with base pair C1409-G1491. The Watson-Crick base
pair C1409-G1491 produces a seat in the pocket at the lower end of
the drug binding site, enabling ring I to stack on G1491. In addition,
N-7 of G1491 forms a hydrogen bond with the O-5 of ring III (2,
29, 31). The MIC data and the calculation of relative resistances
given in Table 2 demonstrate that, within the 6-NH3
 subclass,
ribostamycin is always affected the most by alterations of C1409-
G1491. While ribosomal susceptibility to neamine and neomycin
decreased only moderately upon mutation of the C1409-G1491
base pair (relative resistances between 1 and 16 g/ml), significant
resistance is conferred to ribostamycin (relative resistances between
8 and 128 g/ml). In particular, transversion mutations (G1491 to C
or U and C1409 to G) have a profound effect on ribostamycin
susceptibility. Compared to neomycin and as reported previously
(21), the 6-OH paromomycin is much more dependent on proper
interaction with the C1409-G1491 base pair. The importance of this
interaction is not alleviated by addition of a further amino sugar, as
in lividomycin (Table 2).
The double mutations A1408G/C1409G and A1408G/
G1491U confer high-level drug resistance to all 4,5-aminogly-
cosides tested. This is to be expected for the 6-NH3
 subclass,
due to disruption of the pseudo-base pair interaction of ring I
with A1408 (21, 22). For the 6-OH subclass this finding indi-
cates that the effects of different mutations are more than
additive, in particular for the combined A1408G/C1409G al-
teration, since the relative resistance of the combined A1408G/
C1409G alteration is significantly higher than that of the single
mutations A1408G and C1409G alone (Table 2).
Interactions with base pair U1406 · U1495. The wobble base
pair U1406 · U1495 forms the binding pocket at the upper stem.
One water-mediated contact between O-6 of ring II and O-4 of
U1406 is observed in the 4,5-disubstituted 2-deoxystreptamines
(8, 29). Mutation of U1406 to adenine does not affect drug sus-
ceptibility; alteration of U1406 to cytosine marginally influences
drug susceptibility (relative resistances of 4 to 16 g/ml). The
U1406C/A1408G double mutation results in high-level resistance
to all 4,5-aminoglycosides studied, indicating that for the 6-OH
subclass the effects of the individual mutations are more than
additive.
N-1 of ring II makes an additional direct hydrogen bond con-
tact with O-4 of U1495. The transition mutation U1495C ex-
changes the O-4 with an ammonium group, rendering the
interaction of cytosine with N-1 of the 4,5-aminoglycosides unfa-
vorable (electrostatic repulsion). However, the correct insertion
of ring I into the binding pocket and the pseudo-base pair inter-
FIG. 2. Secondary structure of the bacterial A site (E. coli num-
bering). The introduced mutations are indicated by the arrows, and the
highly conserved A site is boxed. Reprinted from reference 12.
TABLE 1. Strains used in this studya
Strain Reference
mc2155 SMR5 rrnBb ....................................................................... 22
mc2155 SMR5 rrnB A1408Gc........................................................ 22
mc2155 SMR5 rrnB U1406C/U1495Ad ........................................ 22
mc2155 SMR5 rrnB U1406C/U1495Gd ........................................ 12
mc2155 SMR5 rrnB pMV361-hyg-rRNA U1406Ae .................... 22
mc2155 SMR5 rrnB pMV361-hyg-rRNA U1406Ce .................... 22
mc2155 SMR5 rrnB pMV361-hyg-rRNA U1495Ae .................... 22
mc2155 SMR5 rrnB pMV361-hyg-rRNA U1495Ce .................... 22
mc2155 SMR5 rrnB pMV361-hyg-rRNA C1409Ge..................... 21
mc2155 SMR5 rrnB pMV361-hyg-rRNA C1409Ue..................... 21
mc2155 SMR5 rrnB pMV361-hyg-rRNA G1491Ae .................... 21
mc2155 SMR5 rrnB pMV361-hyg-rRNA G1491Ce .................... 21
mc2155 SMR5 rrnB pMV361-hyg-rRNA G1491Ue .................... 21
a Reprinted from reference 12.
b Parental strain with wild-type 16S rRNA.
c Spontaneous mutant of M. smegmatis mc2155 SMR5 rrnB.
d Spontaneous mutant of M. smegmatis mc2155 SMR5 rrnB 1406C generated
by selection on gentamicin (U1406C/U1495A) and amikacin (U1406C/U1495G).
e Recombinant mutant of M. smegmatis mc2155 SMR5 rrnB.
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FIG. 3. Resistance profile of 4,5-disubstituted 2-deoxystreptamines with a 6-NH3
 group (neomycin subclass) represented as comparison
graphs. Each axis of the comparison graph represents the influence of the corresponding introduced mutation (highlighted in bold). The relative
resistances conferred by each of the mutations are plotted in log scale, with the smallest value in the innermost circle. Points lying on the outermost
circle indicate that the corresponding mutations result in a relative resistance outside the measurable range. Neamine and ribostamycin bind weakly
to wild-type ribosomes, and thus, quantitative analysis is limited. To reflect this limitation the values outside the measurable range are depicted
by a hatched area.
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action between O-5 and N-6 of ring I with A1408 still allow
binding of the 6-NH3
 subclass to the ribosome. In contrast, the
6-OH aminoglycosides are more affected by the U1495C alter-
ation. The U1495A alteration is expected to prevent contacts
between N-1 of ring II and nucleotide 1495 even more than a
U-to-C mutation owing to the size of the adenine ring.
With the exception of neomycin, the U1495A alteration as
well as the double mutation U1406C/U1495A confer high-level
drug resistance to all 4,5-aminoglycosides tested, including
neamine, ribostamycin, paromomycin, and lividomycin. Appar-
ently, the interaction of the 6-NH3
 ring I with both A1408
and ring IV is required to partly compensate for this major
conformational change in the ribosomal A site. Unexpectedly,
introducing the U1495G alteration into the U1406C mutant,
thus replacing the U · U wobble base pair with a 1406C-1495G
Watson-Crick interaction, nearly completely restores ribo-
somal susceptibility to the 4,5-aminoglycoside antibiotics.
DISCUSSION
Using a well-defined in vivo system, we investigated the role
of rings III, IV, and V in the binding of 4,5-aminoglycosides to
their ribosomal target. Site-directed mutagenesis of the ribo-
somal A site in a genetic model where manipulation of rRNA
results in cells carrying homogeneous populations of mutant
ribosomes (21–24) allowed a detailed investigation of drug-
target interactions. The critical role of the 6 group of ring I in
the aminoglycoside-ribosome interaction has previously been
investigated by mutagenesis studies and will not be addressed
FIG. 4. Resistance profile of 4,5-disubstituted 2-deoxystreptamines with a 6-OH group (paromomycin subclass) represented as comparison
graphs. Each axis of the comparison graph represents the influence of the corresponding introduced mutation (highlighted in bold). The relative
resistances conferred by each of the mutations are plotted in log scale, with the smallest value in the innermost circle. Points lying on the outermost
circle indicate that the corresponding mutations result in a relative resistance outside the measurable range.
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here (22). In this study we focused on the role of rings III, IV,
and V in drug binding.
In line with previous measurements of dissociation constants
(7) ring III increases drug potency by a factor of 8, as deter-
mined by MIC measurements (Table 2). Ring III makes se-
quence-specific contacts with RNA, i.e., hydrogen bonding be-
tween 5-OH and N-7 of G1491 and between 2-OH and N-4 of
C1407 (2, 29). Addition of ring IV increases the positive net
charge, and it contacts the ribosomal A site at the backbone of
helix 44 (2, 29). The strength of these electrostatic contacts
raises drug activity eightfold as determined by MIC measure-
ments of neomycin and ribostamycin. Overall, in our in vivo
system neomycin is 64-fold more active than neamine. This find-
ing is in good agreement with the dissociation constants reported
for neomycin and neamine (0.5 M versus 100 M) (7). Addition
of ring V affects the antibacterial activity and susceptibility of
mutant ribosomes little, if at all (compare lividomycin to paro-
momycin), indicating that ring V makes only weak contacts with
the A site in a non-sequence-specific manner, most likely with the
RNA backbone, as seen in the crystal structure (8).
For each pair of aminoglycosides with similar properties of
overall charge and substituent at the 6 position, one can divide
the effect of mutations into two categories: mutations for which
the ratio of relative resistance is identical and those for which this
ratio is different. In the neamine-ribostamycin pair, for instance,
the C1409G mutation (and to a lesser extent G1491A or G1491C)
confers higher relative resistance to ribostamycin than to
neamine.
To investigate the ring I-G1491 interaction isolated from
other interactions by additional rings, e.g., between 5-OH of
ring III and N-7 of G1491, we chose a reductionist approach,
i.e., we determined MICs to neamine in a series of mutants
with alterations in the C1409-G1491 base pair. These studies
revealed that transitions affect drug binding weakly; transver-
sions have a small albeit significant effect. We interpret these
findings as evidence that the ring I-G1491 stacking interaction
is largely sequence independent. Within the 6-NH3
 subclass,
ribostamycin is most affected by alterations of the C1409-
G1491 base pair. This finding is rationalized by the X-ray
structural data available for paromomycin (2, 27). In contrast
to ribostamycin, with its ring III-G1491 interaction, neamine
interacts with G1491 merely by non-sequence-specific stacking
interaction with its ring I. Compared to that of ribostamycin,
ring IV of neomycin apparently is able to compensate for the
loss of sequence-specific interaction between ring III and
G1491 and/or introduction of steric clashes as mediated by
mutagenesis of C1409-G1491.
A thorough interpretation of the MIC measurements ob-
tained upon mutagenesis of the U1406 · U1495 wobble base
pair is in part limited by the low susceptibility of wild-type
ribosomes to neamine. Most of the mutations, i.e., U1406C,
U1406A, and U1495C, only moderately affect ribosomal sus-
ceptibility to the 6-NH3
 aminoglycosides, if at all. The
U1495A alteration confers significant resistance to ribostamycin
(relative resistance, 128 g/ml) but only moderately affects sus-
ceptibility to neomycin (relative resistance, 16 g/ml).
The loss of ribosomal susceptibility to neamine and ribosta-
mycin in the U1495A mutant can be rationalized by the loss
of interaction between the 1-amino group of ring II and the
O-4 of U1495 in the U1495A mutant and by less favorable
binding of ring II. Apparently, ring IV of neomycin is able to
partly compensate for this interaction. The U1406C · U1495A
alteration confers high-level drug resistance to all 4,5-aminogly-
cosides except neomycin, which is only moderately affected. As
discussed previously (22), the U1406C · U1495A alteration will
result in a major change in base pair geometry precluding an
appropriate positioning of ring II near the 1406–1495 pair and
consequently poor insertion of ring I in the drug binding pocket.
Alteration of U1495A to G in the U1406C · U1495A double
mutant replaces the natural U1406 · U1495 wobble base pair
with a U1406C-U1495G Watson-Crick base pair and restores
ribosomal susceptibility to all 4,5-aminoglycosides of the 6-
NH3
 and the 6-OH subclasses investigated. This observation
contrasts with the U1406-U1495A alteration, which confers
TABLE 2. Drug susceptibilities of rRNA mutantsa
Mutation(s)
Neomycin subclass Paromomycin subclass
Neamine Ribostamycin Neomycin Paromomycin Lividomycin
MIC (g/ml) RRb MIC (g/ml) RR MIC (g/ml) RR MIC (g/ml) RR MIC (g/ml) RR
None (wild type) 64 8 1 1 2
A1408G 1,024 16 1,024 128 512–1,024 512–1,024 32–64 32–64 64 32
G1491A 64–128 1–2 128 16 4 4 32–64 32–64 256–512 128–256
G1491C 512–1,024 8–16 1,024 128 16–32 16–32 512 512 1,024 512
G1491U 1,024 16 1,024 128 8–16 8–16 512 512 1,024 512
C1409G 128 2 512 64 4 4 16–32 16–32 64–128 32–64
C1409U 256 4 32–64 4–8 1 1 8 8 8–16 4–8
A1408G/C1409G 1,024 16 1,024 128 1,024 1,024 1,024 1,024 1,024 512
A1408G/G1491U 1,024 16 1,024 128 1,024 1,024 1,024 1,024 1,024 512
U1406A 64 1 8 1 1–2 1–2 1 1 1 0.5
U1406C 256–512 4–8 32–64 4–8 2–4 2–4 16 16 8–16 4–8
U1495A 1,024 16 1,024 128 16 16 256–512 256–512 1,024 512
U1495C 256–512 4–8 128 16 8 8 128 128 64–128 32–64
A1408G/U1406C 1,024 16 1,024 128 1,024 1,024 1,024 1,024 1,024 512
U1406C/U1495A 1,024 16 1,024 128 64 64 1,024 1,024 1,024 512
U1406C/U1495G 256 4 32 4 0.5 0.5 2–4 2–4 8–16 4–8
a MIC data for neomycin and paromomycin have been published previously (21, 22) and are included here for comparison.
b RR, relative resistance, calculated by dividing the MIC for the mutant by the MIC for the wild type.
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significant resistance to most 4,5-aminoglycosides. Presumably,
the U1406C-U1495G alteration has a conformation and geom-
etry similar to that of the U1406-U1495A alteration. How then
to explain this difference in drug susceptibility?
One rationale would refer to the different net charge pro-
vided by the functional group at position C-6 of U1495A
(amino group, positive charge) and U1495G (keto group, neg-
ative charge). The keto group at C-6 of 1495G, together with
the N-7 of 1495G, could possibly interact with the ring II N-1
ammonium group in a fashion similar to that of O-4 of the
pyrimidine U1495 or, more generally, be involved in a network
of electrostatic interactions between the positively charged
aminoglycosides and their target RNAs (10, 11). The Hoogsteen
sites of guanines are often involved in binding positive ions such
as potassium ions (1).
Figure 5 shows the superposition of a 1406C-1495G base pair
on the U1406 · U1495 pair. The distances between a typical
aminoglycoside (N-1 and O-6 of ring II) and the Hoogsteen sites
of 1495G are 3.0 Å (O-6) and 4.2 Å (N-7), respectively. It can also
be seen how the amino group N-4 of 1406C may replace the
observed water molecule between U1406 and the aminoglycoside
such that a contact between N-4 of 1406C and O-6 of ring II can
be made. Interestingly, mutants in which a single uracil is replaced
with an adenine display disparate effects. Thus, the U1406-
U1495A mutation leads to resistance to aminoglycosides, while
the U1406A-U1495 mutant shows susceptibility to the neomycin
class of aminoglycosides but less susceptibility to the kanamycin
class (20).
Our data indicate that binding of 4,5-disubstituted aminogly-
cosides to the ribosomal A site depends on proper interaction
of ring I with nucleotides A1408 and G1491 and is further
stabilized by additional contacts, e.g., with U1495. Taken to-
gether, these data on site-directed mutagenesis of the drug
target site provide a detailed analysis of the importance of the
different binding contacts in the drug-ribosome interaction.
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